TLR7 agonist in combination with

We evaluated a novel approach combining the use of attenuated immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated serovar Typhimu...

Full description

Saved in:
Bibliographic Details
Published in:Immunotherapy 2018-06, Vol.10 (8), p.665-679
Main Authors: Vola, Magdalena, Mónaco, Amy, Bascuas, Thais, Rimsky, Geraldine, Agorio, Caroline Isabel, Chabalgoity, José Alejandro, Moreno, María
Format: Article
Language:English
Subjects:
experimental model
imiquimod
immunotherapy
melanoma
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:We evaluated a novel approach combining the use of attenuated immunotherapy with a Toll-like receptor agonist, imiquimod, in B16F1 melanoma-bearing mice. B16F1 melanoma-bearing mice were daily treated with topical imiquimod in combination with one intratumoral injection of attenuated serovar Typhimurium LVR01. The combined therapy resulted in retarded tumor growth and prolonged survival. Combination treatment led to an enhancement in the expression of pro-inflammatory cytokines and chemokines in the tumor microenvironment, with a Th1-skewed profile, resulting in a broad antitumor response. The induced immunity was effective in controlling the occurrence of metastasis. LVR01 immunotherapy in combination with imiquimod is a novel approach that could be considered as an effective antimelanoma therapy.
ISSN:1750-743X
1750-7448
DOI:10.2217/imt-2017-0188